Evidence map›Paper›PMID 26001219›Full record

ArticleCell death and differentiation2016

Intracellular nicotinamide adenine dinucleotide promotes TNF-induced necroptosis in a sirtuin-dependent manner.

N Preyat, M Rossi, J Kers, L Chen, J Bertin, P J Gough, A Le Moine, A Rongvaux, F Van Gool, O Leo

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Cell death and differentiation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06465602 (Nicotinamide Supplementation Improves Physical Performance in Older Adults at Risk of Falls), which is not on this map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06465602 phase2unknown statusnot on this mapstarted 2024, after this paper: background citation

Nicotinamide Supplementation Improves Physical Performance in Older Adults at Risk of Falls: a Pilot Randomized Clinical Trial

TypeinterventionalSponsorUniversity of ChileRan2024 to 2025Enrolled60ConditionsFrailty, Fall, Frailty Syndrome, FallsArmsNicotinamide, Placebo
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 42 citations in OpenAlex.

  1. Conjugated bile acid-driven CD14JHEP reports : innovation in hepatology · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Emerging Roles for SIRT5 in Metabolism and Cancer.Antioxidants & redox signaling · 2018
    Article
  17. Article
  18. Sirtuins Expression and Their Role in Retinal Diseases.Oxidative medicine and cellular longevity · 2017
    Review
  19. Article
  20. An outline of necrosome triggers.Cellular and molecular life sciences : CMLS · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

N PreyatLaboratory of Immunobiology, Institute for Molecular Biology and Medicine, Université Libre de Bruxelles, Gosselies, Belgium.
M RossiInstitute for Medical Immunology, Université Libre de Bruxelles, Gosselies, Belgium.
J KersDepartment of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
L ChenCenter for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, MN 55455, USA.
J BertinPattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, PA 19426, USA.
P J GoughPattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, PA 19426, USA.
A Le MoineInstitute for Medical Immunology, Université Libre de Bruxelles, Gosselies, Belgium.
A RongvauxDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
F Van GoolDiabetes Center, University of California San Francisco, San Francisco, CA, USA.
O LeoLaboratory of Immunobiology, Institute for Molecular Biology and Medicine, Université Libre de Bruxelles, Gosselies, Belgium.
Université Libre de Bruxelles · BEGlaxoSmithKline (United States) · USAcademic Medical Center · NLUniversity of California, San Francisco · USUniversity of Minnesota · USYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cellular necrosis has long been regarded as an incidental and uncontrolled form of cell death. However, a regulated form of cell death termed necroptosis has been identified recently. Necroptosis can be induced by extracellular cytokines, pathogens and several pharmacological compounds, which share the property of triggering the formation of a RIPK3-containing molecular complex supporting cell death. Of interest, most ligands known to induce necroptosis (including notably TNF and FASL) can also promote apoptosis, and the mechanisms regulating the decision of cells to commit to one form of cell death or the other are still poorly defined. We demonstrate herein that intracellular nicotinamide adenine dinucleotide (NAD(+)) has an important role in supporting cell progression to necroptosis. Using a panel of pharmacological and genetic approaches, we show that intracellular NAD(+) promotes necroptosis of the L929 cell line in response to TNF. Use of a pan-sirtuin inhibitor and shRNA-mediated protein knockdown led us to uncover a role for the NAD(+)-dependent family of sirtuins, and in particular for SIRT2 and SIRT5, in the regulation of the necroptotic cell death program. Thus, and in contrast to a generally held view, intracellular NAD(+) does not represent a universal pro-survival factor, but rather acts as a key metabolite regulating the choice of cell demise in response to both intrinsic and extrinsic factors.

Indexed as

ApoptosisCell LineCytoplasmFas Ligand ProteinHumansLigandsNADNecrosisReceptor-Interacting Protein Serine-Threonine KinasesSirtuin 2SirtuinsTumor Necrosis Factor-alphaFASLG protein, humanFas Ligand ProteinLigandsNADReceptor-Interacting Protein Serine-Threonine KinasesRIPK3 protein, humanSIRT2 protein, humanSIRT5 protein, humanSirtuin 2SirtuinsTumor Necrosis Factor-alpha

Identifiers

PMID26001219
PMCPMC4815976
OpenAlexW1558169447

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.